PROSTATE WARRIORS - The latest news about prostate cancer
  • Home
  • Cancer 1O1
  • News
  • Navigator
  • Newsletters
  • Contact
  • Search
  • Menu Menu

BA1106 Antibody Shows Promise in Early Trials In Solid Tumors

April 26, 2025/0 Comments/in Clinical Trial, Not PCa related/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-04-26 19:50:552025-04-26 19:50:55BA1106 Antibody Shows Promise in Early Trials In Solid Tumors

Q702 Drug Shows Promise in Early Trials: Could Be Useful Against Prostate Cancer

April 25, 2025/0 Comments/in Clinical Trial, Not PCa related/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-04-25 20:54:382025-04-25 20:54:38Q702 Drug Shows Promise in Early Trials: Could Be Useful Against Prostate Cancer

A New Potential Treatment For Early Prostate Cancer: TGW101

April 25, 2025/0 Comments/in Clinical Trial, Non-Metastatic, Not PCa related, Phase 1/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-04-25 19:45:182025-04-25 19:45:18A New Potential Treatment For Early Prostate Cancer: TGW101

Phase 1 Results: Personalized Cancer Vaccine PGV001 Shows Promise Across Multiple Cancer Types

April 7, 2025/0 Comments/in Clinical Trial, Not PCa related/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-04-07 07:00:172025-04-07 08:08:30Phase 1 Results: Personalized Cancer Vaccine PGV001 Shows Promise Across Multiple Cancer Types

The Microbiome: A Frontline Barrier and Emerging Ally in Cancer Treatment

February 11, 2025/0 Comments/in Clinical Trial, Not PCa related/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-02-11 10:27:462025-02-11 10:31:23The Microbiome: A Frontline Barrier and Emerging Ally in Cancer Treatment

BR111: A New ADC Therapy That Could Work Also For Prostate Cancer

February 11, 2025/0 Comments/in Clinical Trial, Not PCa related/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-02-11 09:37:332025-02-11 10:32:11BR111: A New ADC Therapy That Could Work Also For Prostate Cancer

Phase 1 Trial of a Polynucleotide Kinase/Phosphatase (PNKP) Inhibitor

January 10, 2025/0 Comments/in Clinical Trial, Not PCa related/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-01-10 08:56:012025-01-10 08:56:01Phase 1 Trial of a Polynucleotide Kinase/Phosphatase (PNKP) Inhibitor

Phase 1 Trial: Simple Dietary Supplement Could Supercharge Cancer-Fighting Immune Cells

December 30, 2024/0 Comments/in Clinical Trial, Not PCa related/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2024-12-30 09:27:272025-01-05 09:22:33Phase 1 Trial: Simple Dietary Supplement Could Supercharge Cancer-Fighting Immune Cells

Menu

  • Home
  • Cancer 1O1
  • News
  • Navigator
  • Newsletters
  • Contact

Categories

Archives

  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • September 2023

Project Navigator


Let's try to finance it!

A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.

Tags

225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy castration-resistant prostate cancer CDK12 clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology olaparib oncolytic virus personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics

Latest Posts

  • Newsletter 23/2025 June 8, 2025
  • Protein Design Leaps Forward Thanks to AI June 5, 2025
  • Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors June 5, 2025
  • UPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC June 5, 2025
© Copyright 2024 - PROSTATE WARRIORS - The latest news about prostate cancer
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlySettings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Other cookies

The following cookies are also needed - You can choose if you want to allow them:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy
Accept settingsHide notification only